Biopharmaceutical company Galera Therapeutics‘ stock price rose 41% after showing results from early-stage testing of its experimental therapy for advanced pancreatic cancer. The company is creating proprietary therapies that can potentially transform radiotherapy in cancer. This therapy is designed to protect normal cells and sensitize cancer cells to radiation.
“The Helix Center was an essential piece in enabling us to assemble the research team and lab space to get our drug candidates into the clinic,” Robert A. Beardsley, PhD, Chief Operating Officer at Galera Therapeutics, said. “Now that Galera is a public company, and our first candidate is completing Phase 3, our labs here continue to play a critical role in both advancing that drug and creating the next generation.”